Unlock instant, AI-driven research and patent intelligence for your innovation.

Influenza vaccine sucked or sprayed through nasal cavity, preparation method

An influenza vaccine and nasal technology, which is applied in the field of nasal inhalation or nasal spray influenza vaccine and preparation thereof, and can solve the problems of reducing immunogenicity and the like

Inactive Publication Date: 2006-08-23
TIANCHONG BIO PHARMACY INST LIAONING PROV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Provided is a nasal inhalation or nasal spray influenza vaccine and a preparation method thereof, which better solves the problems existing in nasal spray vaccines, can meet the needs of different groups of people, and can be stored at normal temperature without reducing immunogenicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza vaccine sucked or sprayed through nasal cavity, preparation method
  • Influenza vaccine sucked or sprayed through nasal cavity, preparation method
  • Influenza vaccine sucked or sprayed through nasal cavity, preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0107] 1. Use the A drug recommended by WHO in 2003 3 (H 3 N 2 ): A 3 / Moscow / 10 / 99;A 1 (H 1 N 1 ): A 1 / NewCaledonis / 20 / 99, type B: B / Johannesburg / 99 three strains of influenza virus were inoculated into 8-11-year-old chicken embryos, cultured at 34°C-35°C for 48-72 hours, harvested allantoic fluid, concentrated by ultrafiltration , Purified by ultracentrifugation, which is the whole influenza virus suspension. After the semi-finished product is tested and qualified, the virus suspension is packed into 1000 ml of soft plastic blood collection agent and sealed, and stored in a refrigerator at 2-8°C for future use.

[0108] 2. A sealed soft plastic blood collection bag with a capacity of 1000ml of qualified influenza trivalent full virus suspension produced according to the quality standards and processes stipulated by the state, placed in a medium-sized hydrostatic press, and processed with a hydrostatic press at a pressure of 250Mp2 for 30 minutes. After being process...

Embodiment 2

[0110] Get the virus suspension after the inactivation of the whole influenza virus, check that the titer of hemagglutinin is 180000 micrograms of the suspension several milliliters (hemagglutinin per milliliter is greater than 70 micrograms), calculate the addition amount of the suspension of the whole influenza virus inactivation, and prepare a refined large Add 500 grams of soybean oil, 40 grams of refined soybean lecithin, 300 grams of Tween, 60 grams of glycerin, add water for injection to 2000 ml, put it in a glass container and mix thoroughly for later use.

Embodiment 3

[0112] 1. Put the qualified influenza trivalent inactivated whole virus and fat emulsion mixture together in a high-speed mixer for 15 minutes, make it fully mixed, put it into the debugged medium-sized nano collider, and inactivate the whole influenza virus and fat emulsion. The fat emulsion mixture is processed by a nano-collider, and the voltage, pressure, and flow are adjusted to crack the virus and fat emulsion mixture into particles of 10-12nm size. After being processed by a nano-collider, put it in a refrigerator at 4-8°C .

[0113] 2. After nanotechnology treatment, the influenza virus and fat emulsion are both 10nm in size. After passing the inspection according to the influenza vaccine quality inspection regulations, the hemagglutinin content per milliliter of the mixed solution must be greater than 70 micrograms. Then it is divided into standard nasal cavity inhalation bottles, freeze-dried, and the hemagglutinin of each person (one bottle) of frozen powder must be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

An inhaled influenza vaccine is prepared from the deactivated influenza virus and nano-class fatty emulsion through proportional mixing. Its advantages are no need of injection, high immunogenicity, no damage to antigen, and high effect.

Description

technical field [0001] The invention relates to a nasal cavity inhalation or nasal cavity spray influenza vaccine and a preparation method thereof, belonging to the technical field of medical biological vaccines. Background technique [0002] Influenza is an acute respiratory infectious disease caused by three types of influenza virus A, B and C. The disease has an acute onset, rapid spread, high morbidity rate, and a certain mortality rate. The mortality rate is relatively high in children and the elderly, causing serious social and economic consequences to humans. Moreover, influenza viruses often undergo antigenic mutations and new subspecies appear. Generally, a worldwide pandemic occurs every 10-15 years; regional epidemics often occur in various places in spring and autumn. So far, there is no effective treatment for humans, and the only way to prevent it is to vaccinate against influenza. Therefore, the development of an influenza vaccine with good immunogenicity, l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/145A61K9/72A61P31/16
Inventor 苟仕金苟鸿鹰王成余王刚
Owner TIANCHONG BIO PHARMACY INST LIAONING PROV